Copyright
©The Author(s) 2023.
World J Gastroenterol. Aug 21, 2023; 29(31): 4706-4735
Published online Aug 21, 2023. doi: 10.3748/wjg.v29.i31.4706
Published online Aug 21, 2023. doi: 10.3748/wjg.v29.i31.4706
miRNA | HBV protein | Expression | Target genes | Abnormal function in HBV-HCC | Ref. |
miR-7 | HBV, HBx | Up | Mapsin | Conferring HBx-mediated anoikis resistance and doxorubicin resistance | [213] |
miR-15a/16 | HBV mRNA | Down | - | Inducing etoposide-induced apoptosis | [173] |
miR-21 | HBV, HBx | Up | Mapsin | Conferring HBx-mediated anoikis resistance and doxorubicin resistance | [213] |
miR-23a | HBV | Down | CCL22 | Inhibiting Tregs recruitment | [103] |
miR-30b-5p | HBp | Up | MINPP1 | Promoting tumor growth, enhancing cell proliferation, promoting cell migration and invasion, regulating glycolytic bypass metabolism | [119] |
miR-34a | HBV | Down | CCL22 | Inhibiting Tregs recruitment | [209] |
miR-103 | HBV, HBx | Up | Mapsin | Conferring HBx-mediated anoikis resistance and doxorubicin resistance | [213] |
miR-107 | HBV, HBx | Up | Mapsin | Conferring HBx-mediated anoikis resistance and doxorubicin resistance | [213] |
miR-124 | HBx | Down | PI3K/Akt | Suppressing CSC differentiation | [157] |
miR-135a-5p | HBc | Up | VAMP2 | Preventing Doxorubicin hydrochloride-induced apoptosis | [212] |
miR-138 | HBV | Down | PD-1 | Regulating cytokine secretion of T cells and improving T-cell immune responses | [208] |
miR-146a | HBV | Up | STAT1 | Suppressing IFN-induced anti-HBV effect | [187] |
miR-152 | HBV | Down | HLA-G | Enhanced NK cytolysis against hepatoma cells | [210] |
miR-193b | HBV | Down | Mcl-1 | Sensitizing sorafenib-induced apoptosis | [57] |
miR-200a/200b/429 | HBx | Down | RICTOR | Impairing HCC stem cell properties, regulating glutamine metabolism, sensitizing the response to anti-PD-L1 immunotherapy | [165,166] |
miR-203a | HBs | Down | BMI1 | Sensitizing 5-FU-induced apoptosis, impairing HCC stem cell properties | [58] |
miR-205 | HBx | Down | ACSL1 | May promote lipogenesis | [141] [206] |
miR-325-3p | HBV | Down | DPAGT1 | Sensitizing the response to Doxorubicin chemotherapy | [201,202] |
miR-329 | HBV, HBx | Down | AFP | Sensitizing chemotherapy induced apoptosis | [214] |
miR-384 | HBV, HBx | Down | PTN/PI3K/AKT/mTORC1 | Inhibiting high glucose-induced lipogenesis | [61] |
miR-429 | HBx | Down | Rab18 | Inhibiting dysregulation of lipogenesis | [205] |
miR-1236 | HBV, HBx | Down | AFP | Sensitizing chemotherapy induced apoptosis | [214] |
miR-3682-3p | HBx | Up | FOXO3/PI3K/AKT1/β-catenin/c-Myc | Promoting HCC stemness | [66] |
miR-5188 | HBx | Up | FOXO1/β-catenin | Resisting the effects of chemotherapy 5-FU, CDDP and EPI, promoting HCC stemness | [67] |
- Citation: Zhang MH, Yuan YF, Liu LJ, Wei YX, Yin WY, Zheng LZY, Tang YY, Lv Z, Zhu F. Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(31): 4706-4735
- URL: https://www.wjgnet.com/1007-9327/full/v29/i31/4706.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i31.4706